17:44 , Sep 7, 2018 |  BC Week In Review  |  Company News

Alkermes in pay-for-performance deal

Alkermes plc (NASDAQ:ALKS) signed a contract with UPMC Health Plan for opioid antagonist Vivitrol naltrexone that links reimbursement of the drug to positive clinical outcomes when treating opioid dependence. Alkermes spokesperson Matthew Henson did not disclose...
18:07 , Aug 31, 2018 |  BC Week In Review  |  Company News

Alkermes, Oklahoma negotiating value-based Medicaid purchasing agreements

The Oklahoma Health Care Authority (OHCA) said it has signed its first contract to negotiate value-based Medicaid purchasing agreements with Alkermes plc (NASDAQ:ALKS) for schizophrenia drug Aristada aripiprazole lauroxil. OHCA is also close to agreements for...
15:12 , Aug 31, 2018 |  BC Extra  |  Company News

Alkermes in pay-for-performance deal

Alkermes plc (NASDAQ:ALKS) signed a contract with UPMC Health Plan for opioid antagonist Vivitrol naltrexone that links reimbursement of the drug to positive clinical outcomes when treating opioid dependence. Alkermes spokesperson Matthew Henson did not disclose...
21:59 , Aug 24, 2018 |  BC Extra  |  Company News

Alkermes, Oklahoma negotiating value-based Medicaid purchasing agreements

The Oklahoma Health Care Authority (OHCA) said it has signed its first contract to negotiate value-based Medicaid purchasing agreements with Alkermes plc (NASDAQ:ALKS) for schizophrenia drug Aristada aripiprazole lauroxil. OHCA is also close to agreements for...
19:25 , Jul 5, 2018 |  BC Week In Review  |  Clinical News

Alkermes' Aristada Initio approved for schizophrenia

FDA approved Aristada Initio aripiprazole lauroxil from Alkermes plc (NASDAQ:ALKS) in combination with oral aripiprazole to initiate treatment of schizophrenia in adults. The company expects to launch the product mid-July. Aristada Initio is an extended-release injectable...
19:21 , Jul 2, 2018 |  BC Extra  |  Company News

New dose regimen for Alkermes' aripiprazole approved

Alkermes plc (NASDAQ:ALKS) said FDA approved Aristada Initio aripiprazole lauroxil in combination with oral aripiprazole for adult schizophrenia patients initiating treatment with Aristada. Aristada previously required three weeks of oral aripiprazole supplementation following the first...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
21:45 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Alkermes to start Phase III of Aripiprazole Lauroxil NanoCrystal Dispersion for schizophrenia

In October, Alkermes plc (NASDAQ:ALKS) said it will begin a double-blind, U.S. Phase IIIb trial of Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD) plus Aristada aripiprazole lauroxil vs. Invega Sustenna paliperidone palmitate from Johnson & Johnson (NYSE:JNJ)...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking more...